The acquisition will complement Medtronic Biologics’ bone and healing portfolio as well as expand the company’s presence in new orthopedic fields, such as foot, ankle and sports medicine. Osteotech products include Grafton demineralizing bone matrix, MagniFuse Bone Grafts and Plexur Biocomposites.
Read the Medtronic release on this acquisition.
Read other coverage on Medtronic:
– Medtronic Conducts Defeat-HF Trials Examining the Use of SCS to Prevent Heart Failure
– Medtronic Eliminates Two Executive Positions as Part of Restructuring
– Medtronic Launches SOVEREIGN Spinal System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
